AAV基因治疗纯合子家族性高胆固醇血症的1期试验
本研究开发了表达LDLR的AAV8载体NGGT006,在Ldlr-/-小鼠和仓鼠中降低LDL-C并减少主动脉斑块,在恒河猴中引起短暂肝酶升高但无严重不良事件。开放标签单臂剂量递增试验中,3例HoFH患者接受7.5×10^12、1.5×10^13和3×10^13 vg kg^-1剂量,耐受良好,无载体相关严重不良事件,所有患者肝酶升高经西罗莫司和甲泼尼龙治疗后恢复。最高剂量患者自治疗后3周起LDL-C从11 mmol l^-1持续降至<1.8 mmol l^-1。
要点
- NGGT006在Ldlr-/-小鼠和仓鼠中降低LDL-C,并减小小鼠主动脉斑块。
- 恒河猴中NGGT006引起短暂肝酶升高,但无严重不良事件。
- 最高剂量HoFH患者LDL-C从11 mmol l^-1持续降至<1.8 mmol l^-1。
核心结论
- NGGT006在HoFH患者中耐受良好,最高剂量患者出现持续LDL-C降低,值得未来进一步研究其安全性和疗效。
研究设计与样本
- 临床前研究在Ldlr-/-小鼠、Ldlr-/-仓鼠和恒河猴中评估NGGT006。
- 开放标签、单臂、剂量递增1期试验纳入3例HoFH患者,剂量分别为7.5×10^12、1.5×10^13和3×10^13 vg kg^-1。
- 主要终点为52周随访期间的安全性和LDL-C降低。
主要发现
- NGGT006在Ldlr-/-小鼠和Ldlr-/-仓鼠中降低LDL-C水平,并减小Ldlr-/-小鼠主动脉斑块大小。
- 恒河猴接受NGGT006后出现短暂肝酶升高,但无严重不良事件。
- 3例HoFH患者治疗耐受良好,无载体相关严重不良事件;所有患者肝酶升高经西罗莫司和甲泼尼龙治疗后恢复。
- 最高剂量患者自治疗后3周起LDL-C从11 mmol l^-1持续降至<1.8 mmol l^-1。
关键数值与推荐
- HoFH患者中超过80%携带LDLR突变。
- 试验剂量为7.5×10^12、1.5×10^13和3×10^13 vg kg^-1。
- 最高剂量患者LDL-C从11 mmol l^-1降至<1.8 mmol l^-1。
临床怎么用
- NGGT006为HoFH患者提供了一种潜在的一次性基因治疗策略,但需进一步研究确认其安全性和疗效。
局限性
- 1期试验为开放标签、单臂设计,样本量仅3例。
- 随访时间为52周,长期安全性和疗效尚未确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Homozygous familial hypercholesterolemia (HoFH) is a rare autosomal disease characterized by severely elevated low-density lipoprotein cholesterol (LDL-C) levels and accelerated atherosclerotic cardiovascular disease. More than 80% of patients with HoFH carry low-density lipoprotein receptor (LDLR) mutations. Here we developed an adeno-associated virus gene therapy designed to express LDLR in the liver and evaluated its safety and efficacy in lowering LDL-C levels in experimental animals and in patients with HoFH. NGGT006, a recombinant adeno-associated virus serotype 8-based vector containing a codon-optimized LDLR complementary DNA, lowered LDL-C levels in Ldlr-/- mice and Ldlr-/- hamsters and decreased aortic plaque size in Ldlr-/- mice. In rhesus monkeys, NGGT006 administration led to transient liver enzyme elevations but no severe adverse events. In an open-label, single-arm, dose-escalation trial, three patients with HoFH received doses of NGGT006 of 7.5 × 1012, 1.5 × 1013 and 3 × 1013 vg kg-1. Primary endpoints included safety and LDL-C reduction over a follow-up of 52 weeks. NGGT006 treatment was well tolerated, with no vector-related severe adverse events. All three patients showed elevations of liver enzymes that were resolved after sirolimus and methylprednisolone therapy. The patient who received the highest dose exhibited a sustained reduction in LDL-C from 11 mmol l-1 to <1.8 mmol l-1 starting at 3 weeks after treatment. These results offer initial insights into the safety and therapeutic potential of NGGT006 and warrant future studies of its safety and efficacy. ClinicalTrials.gov: NCT06125847 .
引用
- Zheng T, Gao G, Xu C, et al. AAV gene therapy for homozygous familial hypercholesterolemia: a phase 1 trial. Nat Med. 2026. PMID: 42243546. doi:10.1038/s41591-026-04441-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。